.svg)
BLOG
The Latest on Solid IO
Human-Based Models Accelerating Immuno-Oncology Drug Development
As pressure grows to generate stronger preclinical evidence earlier in development, biotech companies are increasingly exploring human-based models to improve translational relevance and reduce clinical risk in immuno-oncology programs.
Human-Based Models Accelerating Immuno-Oncology Drug Development
As pressure grows to generate stronger preclinical evidence earlier in development, biotech companies are increasingly exploring human-based models to improve translational relevance and reduce clinical risk in immuno-oncology programs.
Biotech Founder of the Year award for CSO Heidi Haikala
The award was announced at the Biotech Stars Awards by Finnish Bioindustries FIB.
Solid IO on stage at the European DeepTech Week
Solid IO representing the most promising European deep tech startups in life science at European DeepTech Week in Paris in March 2026.
Solid IO receives Instrumentarium Science Foundation grant
Solid IO has been selected as one of three companies to receive a grant from the Instrumentarium Science Foundation.
Lee-Anne Zinetti joins Solid IO’s Advisors
We are pleased to welcome Lee-Anne as an advisor to Solid IO, supporting our work with pharmaceutical and biotechnology partners and the commercialization pathway of diagnostics.
Shape the future of cancer care
Join SolidIO in transforming cancer care with groundbreaking organ-on-chip technology. We’re calling on researchers, clinicians, and investors to partner with us in advancing precision medicine, accelerating innovation, and expanding global access to personalized oncology. Together, we can bring clarity and better outcomes to cancer care worldwide.